FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Bid/Ask 16:42:42 28/05/2024 BST | After market 20:00:56 | |||
| 19.4 EUR | -12.22% |
|
19.56 | +0.85% |
| Current month | +11.62% | ||
| 1 month | +8.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 19.4 | -12.22% |
| 27/05/24 | 22.1 | +0.82% |
| 24/05/24 | 21.92 | -5.03% |
| 23/05/24 | 23.08 | +3.78% |
| 22/05/24 | 22.24 | -3.26% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 04:42 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD4ZQ3 |
| ISIN | DE000SD4ZQ32 |
| Date issued | 26/03/2021 |
| Strike | 7,135 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 11.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 53.32 € |
|---|---|
| Lowest since issue | 7 € |
| Spread | 0.59 € |
| Spread % | 2.98% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
156.7
USD
Average target price
170.1
USD
Spread / Average Target
+8.55%
- Stock Market
- Certificates
- Certificat
